433 related articles for article (PubMed ID: 31423333)
41. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sandigursky S; Mor A
Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
[TBL] [Abstract][Full Text] [Related]
42. The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.
Simmons D; Lang E
Cureus; 2017 Oct; 9(10):e1774. PubMed ID: 29250474
[TBL] [Abstract][Full Text] [Related]
43. Immunological Agents Used in Cancer Treatment.
Simsek M; Tekin SB; Bilici M
Eurasian J Med; 2019 Feb; 51(1):90-94. PubMed ID: 30911265
[TBL] [Abstract][Full Text] [Related]
44. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
45. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
46. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
47. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
48. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Choi J; Lee SY
Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597
[TBL] [Abstract][Full Text] [Related]
49. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.
Weber JS
Am Soc Clin Oncol Educ Book; 2012; ():174-7. PubMed ID: 24451730
[TBL] [Abstract][Full Text] [Related]
50. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
[TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients.
Van Mol P; Donders E; Lambrechts D; Wauters E
Int Rev Cell Mol Biol; 2024; 382():181-206. PubMed ID: 38225103
[TBL] [Abstract][Full Text] [Related]
52. B cells as biomarkers: predicting immune checkpoint therapy adverse events.
Liudahl SM; Coussens LM
J Clin Invest; 2018 Feb; 128(2):577-579. PubMed ID: 29309049
[TBL] [Abstract][Full Text] [Related]
53. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
54. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.
Hasan Ali O; Berner F; Bomze D; Fässler M; Diem S; Cozzio A; Jörger M; Früh M; Driessen C; Lenz TL; Flatz L
Eur J Cancer; 2019 Jan; 107():8-14. PubMed ID: 30529903
[TBL] [Abstract][Full Text] [Related]
55. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.
Anderson D; Beecher G; Nathoo N; Smylie M; McCombe JA; Walker J; Jassal R
Neurooncol Pract; 2019 Sep; 6(5):340-345. PubMed ID: 31555448
[TBL] [Abstract][Full Text] [Related]
56. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.
Arnaud-Coffin P; Maillet D; Gan HK; Stelmes JJ; You B; Dalle S; Péron J
Int J Cancer; 2019 Aug; 145(3):639-648. PubMed ID: 30653255
[TBL] [Abstract][Full Text] [Related]
57. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
58. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
59. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
[TBL] [Abstract][Full Text] [Related]
60. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]